How Will the Market React to Tonix Pharmaceuticals Holding Corp (TNXP) Stock Getting a Bearish Rating

Overall market sentiment has been down on Tonix Pharmaceuticals Holding Corp (TNXP) stock lately. TNXP receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Tonix Pharmaceuticals Holding Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TNXP!

See Full TNXP Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With TNXP Stock Today?

Tonix Pharmaceuticals Holding Corp (TNXP) stock is trading at $1.34 as of 10:29 AM on Friday, Aug 19, a drop of -$0.06, or -4.64% from the previous closing price of $1.40. The stock has traded between $1.31 and $1.39 so far today. Volume today is low. So far 1,073,275 shares have traded compared to average volume of 11,731,905 shares.

More About Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. Click Here to get the full Stock Report for Tonix Pharmaceuticals Holding Corp stock.